Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Uvistat sun cream SPF 50
130801000BBKNA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 4,170 |
|
Sunsense daily face cream SPF 50+
130801000BBNTA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 2,245 |
|
Sunsense ultra lotion SPF 50+
130801000BBLIA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 2,239 |
|
Anthelios sunscreen lotion SPF 50+
130801000BBPYA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 1,804 |
|
Uvistat sun cream SPF 30
130801000BBNSA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 521 |
|
Uvistat lipscreen SPF 50
130801000BBNQA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 269 |
|
Sunsense sensitive cream SPF 50+
130801000BBPTA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 245 |
|
Anthelios XL cream SPF 50+
130801000BBNWA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 136 |
|
Sunsense lip balm SPF 50
130801000BBNUA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 87 |
|
Ultrasun Family lotion SPF 30
130801000BBPFA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 38 |
|
Ultrasun anti-ageing face cream SPF 30
130801000BBPHA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 36 |
|
Delph sun lotion SPF 30
130801000BBKZA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 32 |
|
Ultrasun Extreme lotion SPF 50+
130801000BBPEA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 31 |
|
Sunsense sunsensitive cream SPF 50+
130801000BBNVA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 29 |
|
Sunsense kids lotion SPF 50+
130801000BBPUA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 23 |
|
Delph sun lotion SPF 50+
130801000BBPIA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 13 |
|
Sunsense toddler milk lotion SPF 50+
130801000BBMAA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 11 |
|
Ultrasun Sports gel SPF 20
130801000BBPBA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 9 |
|
Ultrasun anti-ageing face cream SPF 50+
130801000BBPGA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 8 |
|
Riemann P20 lotion SPF 20
130801000BBNYA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 7 |
|
Riemann P20 spray SPF 50
130801000BBPXA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 5 |
|
Ambre Solaire UV Sensitive protection milk SPF 50+
130801000BBNXA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 3 |
|
Riemann P20 Once a Day sunfilter lotion SPF 50
130801000BBPAA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 2 |
|
Sunsense anti-ageing face lotion SPF 50
130801000BBPCA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 2 |
|
Riemann P20 Once a Day sunfilter lotion SPF 30
130801000BBNZA0
|
Proprietary compound preparation BNF 1308010 | Other sunscreening preparations | Skin | 1 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.